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Summary
Introduction:  Parathyroid  carcinomas  are  rare  and  usually  difﬁcult  to  diagnose,  both  clinically
and histologically.
Case  report:  A  60-year-old  man  was  hospitalised  for  hypotension.  Investigations  revealed  renal
failure associated  with  hypercalcaemia  and  elevated  serum  parathormone. 99mTc-sestamibi
scintigraphy  of  the  parathyroid  glands  (PT)  revealed  a  mass  in  the  right  PT  that  was  treated
by parathyroidectomy  and  recurrent  laryngeal  lymph  node  dissection.  Histological  examination
demonstrated  a  tumour  with  numerous  cytonuclear  atypias  and  immuno-histochemistry  demon-
strated PTH  expression  by  tumour  cells  without  loss  of  paraﬁbromin  expression.  The  diagnosis
of PTC  was  based  on  criteria  of  invasion  and  local  aggressiveness,  despite  the  absence  of  lymph
node metastasis.  The  patient  developed  four  recurrences,  treated  surgically  and  by  adjuvant
radiotherapy.
Discussion:  The  diagnosis  of  PTC  is  usually  difﬁcult  to  establish  on  a  simple  histological  exami-
nation in  the  absence  of  speciﬁc  cytological,  architectural  or  immuno-histochemical  markers.
This diagnosis  must  therefore  be  based  on  a  combination  of  clinical,  radiological  and  histological
signs in  a  context  of  atypical  presentation  of  parathyroid  tumour.
.  All  
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IntroductionParathyroid  carcinoma  (PTC)  is  a  very  rare  disease.  This
case  report  illustrates  the  difﬁculties  encountered  during
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he  histological  diagnosis  of  PTC  in  order  to  improve  the
anagement  of  this  disease.
ase report
e  report  the  case  of  a  60-year-old  man  with  a history  of
ypertension,  who  consulted  in  July  2006  for  deterioration
f  his  general  state  of  health,  and  who  was  hospitalised
or  hypotension.  The  laboratory  work-up  revealed  renal
ailure  associated  with  hypercalcaemia  and  elevated  serum
served.
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tigure  1  Medium  to  large  tumour  cells  with  marked  cytonu-
lear atypias  and  mitotic  ﬁgures  (arrow).  (HE  ×400.)
arathormone. 99mTc-sestamibi  scintigraphy  of  the  parathy-
oid  glands  (PT)  revealed  a  mass  of  the  right  PT.  Right
arathyroidectomy  and  recurrent  laryngeal  lymph  node  dis-
ection  were  performed.  Macroscopically,  the  PT  measured
.5  cm  and  weighed  4.10  grams.  On  section,  it  comprised
 whitish  zone,  2  cm  in  diameter,  with  a  ﬁrm  consistency
omprising  ﬁbrous  and  haemorrhagic  features.  Histological
xamination  revealed  a  tumour  composed  of  medium  to
arge  cells  arranged  in  lobules  or  sometimes  masses,  giving
 pseudonodular  appearance.  Numerous  cytonuclear  atyp-
as  were  observed,  with  irregular,  nucleolated  nuclei,  and
ntense  mitotic  activity  (Fig.  1).  The  periphery  of  the  tumour
as  inconstantly  demarcated  by  a  capsule  and  numerous
mages  of  vascular  invasion  were  observed  (Fig.  2).  Immuno-
istochemistry  showed  that  tumour  cells  expressed  PTH
Fig.  3)  with  no  loss  of  paraﬁbromin  expression.  The  diag-
osis  of  PTC  was  based  on  the  criteria  of  invasion  and  local
ggressiveness,  despite  the  absence  of  lymph  node  metas-
asis  on  the  recurrent  laryngeal  lymph  node  dissection.  The
atient  developed  four  recurrences  between  2008  and  2011,
igure  2  Numerous  vascular  emboli  at  the  periphery  of  the
umour  (arrow)  (HE  ×100).
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tigure  3  Immuno-histochemistry:  all  tumour  cells  are  stained
y PTH  antibody  (×400).
reated  surgically  by:  total  thyroidectomy,  bilateral  neck
issection,  and  resection  of  retrotracheal,  mediastinal  and
ara-oesophageal  lesions.  Postoperative  follow-up  demon-
trated  a  marked  reduction  of  serum  calcium  and  serum
TH,  which  were  the  markers  of  recurrence.  In  the  context
f  these  recurrences  and  the  possibility  of  residual  disease,
djuvant  radiotherapy  was  delivered.
iscussion
TC  is  a  very  rare  disease,  diagnosed  in  less  than  1%
f  patients  with  elevated  serum  parathormone  levels
1—4]. PTC  is  usually  an  isolated,  hyper-secreting  malignant
umour,  which  can  be  difﬁcult  to  diagnose  in  the  absence  of
etastases.
The  sex-ratio  is  close  to  1  [3—5]  and  the  mean  age
f  onset  is  50  years  [4].  The  aetiology  remains  unknown,
lthough  genetic  predisposition  factors,  such  as  primary
yperparathyroidism  (PHP)  with  jaw  tumour,  or  risk  factors
uch  as  irradiation  have  been  described  [2,5]. The  clinical
resentation  is  variable,  usually  comprising  renal  failure,
s  in  the  case  reported  here  [4].  A  palpable  neck  mass
s  present  in  15  to  75%  of  cases,  depending  on  the  series
1,3].  Macroscopically,  the  tumour  may  resemble  an  ade-
oma.  However  carcinomas  are  often  multinodular,  with  a
rm  consistency,  a grayish  colour,  presenting  necrotic  fea-
ures  and  adhesions  [3,5]. The  criteria  of  malignancy  were
nitially  described  in  1973  by  Shantz  and  Castleman:
 presence  of  a  lobular  architecture  separated  by  ﬁbrous
trabeculae;
 cytonuclear  atypias;
 mitotic  ﬁgures.  However,  these  criteria  are  inconstantly
observed  [2—7]. According  to  the  World  Health  Organi-
zation,  no  speciﬁc  criterion  of  malignancy  has  yet  been
identiﬁed.Certain  criteria  must  be  investigated  in  order  to  conﬁrm
he  diagnosis:
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•  presence  of  vascular  invasion  (in  the  capsule  or  adjacent
tissues);
• capsular  invasion  with  extension  to  adjacent  tissues
and/or;
•  presence  of  metastases.
A  triad  of  high-risk  histological  features  is  also  asso-
ciated  with  an  aggressive  clinical  behaviour:  presence
of  coagulation  necrosis,  large  nucleoli  and  more  than
ﬁve  mitotic  ﬁgures  per  ten  high-power  ﬁelds  [3].  In  the
present  case,  the  locally  very  aggressive  features  with  inva-
sion  of  adjacent  structures  constituted  the  basis  for  the
diagnosis  of  malignancy,  despite  the  absence  of  metasta-
sis.
The  main  differential  diagnosis  is  parathyroid  adenoma,
but  parathyroid  hyperplasia,  anaplastic  thyroid  cancer  or,
more  rarely,  metastasis  of  renal  cell  carcinoma,  must  also
be  excluded.
Mutations  inactivating  the  HRPT2  gene  have  been
observed  in  hereditary  hyperparathyroidism  with  jaw
tumour  syndromes,  and  sporadic  PTC.  This  gene  codes  for
paraﬁbromin,  a  protein  that  can  be  detected  by  immuno-
histochemistry  and  whose  role  has  not  yet  been  fully
elucidated  [8].  The  sensitivity  and  speciﬁcity  of  the  corre-
lation  between  malignancy  and  decreased  or  absent  nuclear
expression  of  paraﬁbromin  are  67%  and  100%,  respectively.
A  more  recent  study  showed  that  the  association  of  loss
of  paraﬁbromin  expression  and  the  combined  protein  prod-
uct  of  the  9.5  gene  (PGP9.5)  increases  the  presumption  of
malignancy  [9].
Immuno-histochemistry  using  an  anti-PTH  antibody  has
not  been  demonstrated  to  be  useful  for  the  diagnosis  of
malignancy.  A  proliferation  index,  evaluated  by  the  Ki  67
antibody,  higher  than  5%  is  associated  with  a  higher  risk  of
malignancy  and  recurrence  [3].  Overexpression  of  cyclin  D1
or  inactivation  of  the  retinoblastoma  gene  cannot  be  used
to  reliably  differentiate  parathyroid  adenoma  from  parathy-
roid  carcinoma  [1].
The  recurrence  rate  of  PTC  ranges  between  30  and
67%.  Hypercalcaemia  is  often  the  ﬁrst  sign  of  these  recur-
rences.  According  to  the  literature,  the  5-year  survival
is  40  to  86%  and  the  10-year  survival  is  49%  [4,5,10].
In  more  than  30%  of  cases,  metastases  occur  in  regional
lymph  nodes  (30—40%),  lungs  (20—40%)  and,  more  rarely,
in  the  mediastinum,  bone,  pleura,  pericardium  or  pancreas
[1,4,10].  Treatment  is  essentially  surgical  [2—10], with  ‘‘en
bloc’’  resection  including  the  tumour,  the  ipsilateral  thy-
roid  lobe,  ipsilateral  recurrent  laryngeal  and  jugular  and
carotid  lymph  nodes,  and  pretracheal  adipose  tissue.  The
efﬁcacy  of  adjuvant  therapy  has  not  been  clearly  demon-
strated.
[159
onclusion
he  diagnosis  of  PTC  is  usually  difﬁcult  to  establish  on  the
asis  of  simple  histological  examination  in  the  absence  of
peciﬁc  cytological,  architectural  or  immuno-histochemical
arkers  and  is  therefore  based  on  a  combination  of  clini-
al,  radiological  and  histological  signs  in  the  context  of  an
typical  presentation  of  PT  tumour  and,  whenever  possi-
le,  before  the  appearance  of  metastases.  However,  it  is
ot  uncommon  for  a  ﬁnal  diagnosis  of  malignancy  to  be
stablished  only  at  the  stage  of  recurrence  or  metastases.
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